Shen Wenbin,Xu Jinrui,Li Shuguang,Li Youmei,Song Chunyang,Zhao Yan,Zhu Shuchai.Analyses of therapeutic effects and prognosis of patients with postoperative recurrent esophageal cancer[J].Chinese Journal of Radiological Medicine and Protection,2021,41(9):678-684
Analyses of therapeutic effects and prognosis of patients with postoperative recurrent esophageal cancer
Received:December 09, 2020  
DOI:10.3760/cma.j.issn.0254-5098.2021.09.007
KeyWords:Postoperative recurrence of esophageal cancer  Operation  Radiotherapy  Chemotherapy  Prognosis
FundProject:
Author NameAffiliationE-mail
Shen Wenbin Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhaung 050011, China  
Xu Jinrui Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhaung 050011, China  
Li Shuguang Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhaung 050011, China  
Li Youmei Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhaung 050011, China  
Song Chunyang Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhaung 050011, China  
Zhao Yan Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhaung 050011, China  
Zhu Shuchai Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhaung 050011, China sczhu1965@163.com 
Hits: 1710
Download times: 811
Abstract::
      Objective To analyze the therapeutic effects and prognosis after radiotherapy (chemotherapy) of patients with postoperative recurrent esophageal cancer. Methods This study analyzed 501 patients with postoperative recurrent esophageal cancer who were treated in the Radiotherapy Department of the Fourth Hospital of Hebei Medical University and met enrollment conditions. Among them, 274 patients received concurrent chemotherapy and radiotherapy. The analyses in this study focused on the survival after the retreatment, postoperative recurrence patterns, prognosis of retreatment, and prognostic factors affecting the retreatment. Meanwhile, statistical analysis was conducted using the software SPSS Statistics 19.0. Results The time of postoperative recurrence was 0.3-87.4 months, with a median number of 11.6 months. The median survival time was 12.1 months after the retreatment. Among all the patients, 344 patients suffered from only local recurrence, while the remaining 157 patients experienced distant metastasis. According to multivariate analysis result, independent prognostic factors included gender, pN stage, lymph node positive logarithmic ratio (LODDS), the number of chemotherapy cycles, time of recurrence, and distant metastasis (P < 0.05). Meanwhile, prognostic factors affecting the 344 patients with only local recurrence included the time of recurrence, the number of chemotherapy cycles, and prescription dose (χ2=22.605, 13.957, 10.446; P< 0.05). The remaining 157 patients suffered from distant metastasis. The 1-, 3-, and 5-year survival rates of them were 43.3%, 9.1%, and 5.5%, respectively, and those of the patients with only local recurrence were 53.6%, 22.6%, and 16.4%, respectively. The differences were statistically significant (χ2=10.786, P< 0.05). Conclusions Radiotherapy (chemotherapy) is safe and effective for the treatment of recurrent esophageal cancer. However, it features poor prognosis for male patients with a late pN stage, a high LODDS, the number of chemotherapy cycles ≤ 2, the time of recurrence ≤ 24 months, and distant metastasis.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:9070403  On-line:0

v
Scan QR Code
&et=187D67CB317A20759F197A0A001167C2383838629D1618756FA5493AB9E0D03C8626FA5298CE7EBAC3B9D7EF627539EC8ED643AEDF196B1EBBCC311CB3A24596F2D5214EEE694B57D3B3E206E461ACD34380062C77355D61A8FC8EF2387C22B23F9BD94A4714FF711CB17FDDF77F01B3&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=9475FABC7A03F4AB&aid=5344E8CDAB491ECE786B2D2B69C46331&vid=&iid=9CF7A0430CBB2DFD&sid=DA280A426E11FC95&eid=47122BA7BE181C5A&fileno=20210907&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="9475FABC7A03F4AB"; var my_aid="5344E8CDAB491ECE786B2D2B69C46331";